In a phase II clinical trial of advanced pancreatic cancer patients treated with IGF1R-directed monoclonal antibody MK-0646 combined with gemcitabine, high expression of IGF1 in the combined treatment group was found to be associated with reduced risk of disease progression or death [42]. This evidence concerns the gene IGF1R and familial pancreatic carcinoma.